Rozzano

• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit … Recruiting
  2024-520101-39-00 5 2026-04-01 TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
• LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting
  2025-522338-30-00 4 2026-03-31 Ulcerative Colitis
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 5 2026-03-24 Metabolic Dysfunction-Associated Steatotic Liver Disease
• Zanubritnib and anti-MAG neuropathy Recruiting
  2025-523091-23-00 4 2026-03-24 Peripheral anti-MAG neuropathy, waldenstrom macroglobulinemia, margina
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• (Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with … Recruiting
  2024-520026-11-00 7 2026-03-19 Metastatic Prostate Cancer
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin … Recruiting
  2024-518210-81-00 5 2026-03-18 Advanced Hepatocellular Carcinoma
• ROMANCE Recruiting
  2025-521319-38-00 4 2026-03-11 metastatic colorectal cancer
• A trial to learn how well AZD4144 works, how safe it is, and how it moves throughout the body over time in adults with acute kidney injury c … Recruiting
  2025-522232-13-00 4 2026-03-06 Sepsis-associated acute kidney injury (AKI)
• Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com … Recruiting
  2025-521284-12-00 5 2026-03-05 Non-small cell lung cancer
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab ( Switch-Up ) Recruiting
  2025-523347-35-00 11 2026-03-05 Atopic Dermatitis
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004) Recruiting
  2025-523412-36-00 3 2026-02-17 Systemic lupus erythematosus, Rheumatoid arthritis
• Zasocitinib in Nonsegmental Vitiligo Recruiting
  2025-522309-40-00 4 2026-02-11 Non-segmental vitiligo
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat … Recruiting
  2025-521873-15-00 9 2026-02-09 Metastatic hormone-sensitive prostate cancer
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting
  2025-522333-61-00 4 2026-01-23 Hidradenitis suppurativa
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma

Showing 145–168 of 705 trials